Chemokines in experimental autoimmune encephalomyelitis and multiple sclerosis

Advances in Experimental Medicine and Biology

Volumn 520, Issue , 2003, Pages 120-132

  Babcock, Alicia ^a   Owens, Trevor ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; BETA INTERFERON; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CORTICOSTEROID; DNA VACCINE; GLATIRAMER; GROWTH RELATED ONCOGENE PROTEIN ALPHA; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOKINE; PROTEIN ANTIBODY; RANTES; T CELL ACTIVATION PROTEIN 10; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CELL; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE RELEASE; DRUG EFFECT; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LEUKOCYTE; MACROPHAGE; MICROGLIA; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0038748381     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0171-8_8     Document Type: Review

References (75)

1. Rossi D, Zlomik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217-242.
2. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18:593-620.
3. Yoshida T, Imai T, Kakizaki M et al. Identification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem 1998; 273:16551-16554.
4. Kelner GS, Kennedy J, Bacon KB et al. Lymphotactin: A cytokine that represents a new class of chemokine. Science 1994; 266:1395-1399.
5. Schwaeble WJ, Stover CM, Schall TJ et al. Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett 1998; 439:203-207.
6. Harrison JK, Jiang Y, Chen S et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 1998; 95:10896-10901.
7. Clark-Lewis I, Schumacher C, Baggiolini M et al. Structureactivity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem 1991; 266:23128-23134.
8. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a preB-cell growth-stimulating factor. Proc Natl Acad Sci USA 1994; 91:2305-2309.
9. Aiuti A, Turchetto L, Cota M et al. Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Blood 1999; 94:62-73.
10. Poznansky MC, Olszak IT, Foxall R et al. Active movement of T cells away from a chemokine. Nat Med 2000; 6:543-548.
11. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61:246-257.
12. Murphy PM, Baggiolini M, Charo IF et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52:145-176.
13. Mennicken F, Maki R, de Souza EB et al. Chemokines and chemokine receptors in the CNS: A possible role in neuroinflammation and patterning. Trends Pharmacol Sci 1999; 20:73-78.
14. Asensio VC, Campbell IL. Chemokines in the CNS: Plurifunctional mediators in diverse states. Trends Neurosci 1999; 22:504-512.
15. Murphy PM. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 1997; 34:311-318.
16. Weng Y, Siciliano SJ, Waldburger KE et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 1998; 273:18288-18291.
17. Lu B, Humbles A, Bota D et al. Structure and function of the murine chemokine receptor CXCR3. Eur J Immunol 1999; 29:3804-3812.
18. Uguccioni M, Loetscher P, Forssmann U et al. Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J Exp Med 1996; 183:2379-2384.
19. Owens T, Sriram S. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol Clin 1995; 13:51-73.
20. Trapp BD, Ransohoff RRudick R. Axonal pathology in multiple sclerosis: Relationship to neurologic disability. Curr Opin Neurol 1999; 12:295-302.
21. Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.
22. Arnason BG. Immunologic therapy of multiple sclerosis. Annu Rev Med 1999; 50:291-302.
23. Genain CP, Zamvil SS. Specific immunotherapy: One size does not fit all. Nat Med 2000; 6:1098-1100.
24. Tran EH, Hoekstra K, van Rooijen N et al. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol 1998; 161:3767-3775.
25. Owens T, Wekerle H, Antel J. Genetic models for CNS inflammation. Nature Medicine 2001; 7:161-166.
26. Owens T, Tran E, Hassan-Zahraee M et al. Immune cell entry to the CNS - A focus for immunoregularion of EAE. Res Immunol 1998; 149:781-789; discussion 844-786, 855-760.
27. Laflamme N, Lacroix S, Rivest S. An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 1999; 19:10923-10930.
28. Owens T, Renno T, Taupin V et al. Inflammatory cytokines in the brain: Does the CNS shape immune responses? Immunol Today 1994; 15:566-571.
29. Krakowski ML, Owens T. Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur J Immunol 2000; 30:1002-1009.
30. Tan J, Town T, Suo Z et al. Induction of CD40 on human endothelial cells by Alzheimer's beta-amyloid peptides. Brain Res Bull 1999; 50:143-148.
31. Loetscher P, Uguccioni M, Bordoli L et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391:344-345.
32. Glabinski AR, Tani M, Tuohy VK et al. Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain Behav Immun 1995; 9:315-330.
33. Karpus WJ, Lukacs NW, McRae BL et al. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155:5003-5010.
34. Kennedy KJ, Strieter RM, Kunkel SL et al. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol 1998; 92:98-108.
35. Glabinski AR, Tuohy VK, Ransohoff RM. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998; 5:166-171.
36. Miyagishl R, Kikuchi S, Takayama C et al. Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol 1997; 77:17-26.
37. Nygardas PT, Maatta JA, Hinkkanen AE. Chemokine expression by central nervous system resident cells and infiltrating neutrophils during experimental autoimmune encephalomyelitis in the BALB/c mouse. Eur J Immunol 2000; 30:1911-1918.
38. Youssef S, Wildbaum G, Maor G et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161:3870-3879.
39. Godiska R, Chantry D, Dietsch GN et al. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58:167-176.
40. Asensio VC, Lassmann S, Pagenstecher A et al. C10 is a novel chemokine expressed in experimental inflammatory demyelinating disorders that promotes recruitment of macrophages to the central nervous system. Am J Pathol 1999; 154:1181-1191.
41. Tani M, Fuentes ME, Peterson JW et al. Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J Clin Invest 1996; 98:529-539.
42. McColl SR, Staykova MA, Wozniak A et al. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J Immunol 1998; 161:6421-6426.
43. Traugott U, McFarlin DE, Raine CS. Immunopathology of the lesion in chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Cell Immunol 1986; 99:395-410.
44. Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996; 26:1641-1646.
45. Tran EH, Prince EN, Owens T. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 2000; 164:2759-2768.
46. Glabinski AR, Tani M, Strieter RM et al. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 1997; 150:617-630.
47. Tani M, Glabinski AR, Tuohy VK et al. In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am J Pathol 1996; 148:889-896.
48. Youssef S, Wildbaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J Autoimmun 1999; 13:21-29.
49. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30:1410-1415.
50. Rottman JB, Slavin AJ, Silva R et al. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 2000; 30:2372-2377.
51. Fife BT, Huffnagle GB, Kuziel WA et al. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192:899-906.
52. Izikson L, Klein RS, Charo IF et al. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000; 192:1075-1080.
53. Kivisakk P, Teleshova N, Ozenci V et al. No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. J Neuroimmunol 1998; 91:108-112.
54. Zang YC, Samanta AK, Halder JB et al. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain 2000; 123:1874-1882.
55. Balashov KE, Rottman JB, Weiner HL et al. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999; 96:6873-6878.
56. Sorensen TL, Tani M, Jensen J et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103:807-815.
57. Miyagishi R, Kikuchi S, Fukazawa T et al. Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 1995; 129:223-227.
58. Simpson JE, Newcombe J, Cuzner ML et al. Expression of monocyte chemoattractant protein-1 and other beta- chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998; 84:238-249.
59. McManus C, Berman JW, Brett FM et al. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998; 86:20-29.
60. Van Der Voorn P, Tekstra J, Beelen RH et al. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999; 154:45-51.
61. Simpson J, Rezale P, Newcombe J et al. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000; 108:192-200.
62. Simpson JE, Newcombe J, Cuzner ML et al. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000; 26:133-142.
63. Bennetts BH, Teutsch SM, Buhler MM et al. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58:52-59.
64. Barcellos LF, Schito AM, Rimmler JB et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple sclerosis Genetics Group. Immunogenetics 2000; 51:281-288.
65. Sellebjerg F, Madsen HO, Jensen CV et al. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102:98-106.
66. Fiten P, Vandenbroeck K, Dubois B et al. Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. J Neuroimmunol 1999; 95:195-201.
67. Teuscher C, Butterfield RJ, Ma RZ et al. Sequence polymorphisms in the chemokines Scyal (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J Immunol 1999; 163:2262-2266.
68. Zou YR, Kottmann AH, Kuroda M et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development [see comments]. Nature 1998; 393:595-599.
69. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999; 286:2098-2102.
70. Boehme SA, Lio FM, Maciejewski-Lenoir D et al. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol 2000; 165:397-403.
71. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 1996; 17:553-565.
72. Meda L, Bernasconi S, Bonaiuto C et al. Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactlc cytoklne MCP-1/JE in monocytes and microglial cells. J Immunol 1996; 157:1213-1218.
73. Jensen MB, Hegelund IV, Lomholt ND et al. IFNgamma enhances microglial reactions to hippocampal axonal degeneration. J Neurosci 2000; 20:3612-3621.
74. Hausmann EH, Berman NE, Wang YY et al. Selective chemokine mRNA expression following brain injury. Brain Res 1998; 788:49-59.
75. Galasso JM, Harrison JK, Silverstein FS. Excitotoxic brain injury stimulates expression of the chemokine receptor CCR5 in neonatal rats. Am J Pathol 1998; 153:1631-1640.